Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American heart failure trial

American Journal of Cardiology

Volumn 114, Issue 1, 2014, Pages 151-159

  Ferdinand, Keith Copelin ^a   Elkayam, Uri ^b   Mancini, Donna ^c   Ofili, Elizabeth ^d   Piña, Ileana ^e   Anand, Inder ^f   Feldman, Arthur Michael ^g   McNamara, Dennis ^h   Leggett, Christopher ⁱ  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c College of Physi and Surg ^*  (United States)

^d MOREHOUSE SCHOOL OF MEDICINE   (United States)

^e MONTEFIORE MEDICAL CENTER   (United States)

^f VA MEDICAL CENTER   (United States)

^g TEMPLE UNIVERSITY HEALTH SYSTEM   (United States)

^h UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

ⁱ East Georgia Regional Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE SYNTHASE; ENALAPRIL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDRALAZINE; ISOSORBIDE DINITRATE; PEROXYNITRITE; REACTIVE OXYGEN METABOLITE;

AFRICAN AMERICAN; ALLELE; ARTHRALGIA; ARTICLE; BIOEQUIVALENCE; CARDIAC PATIENT; CONGESTIVE CARDIOMYOPATHY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; EXERCISE TOLERANCE; FOLLOW UP; GENE FREQUENCY; GENETIC DIFFERENCE; GENETIC RISK; HEADACHE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE HYPERTROPHY; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPOTENSION; MEDICATION COMPLIANCE; MITOCHONDRIAL RESPIRATION; NEW YORK HEART ASSOCIATION CLASS; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RACE; SOCIAL SUPPORT; SURVIVAL; VASCULAR DISEASE;

AFRICAN AMERICANS; DRUG COMBINATIONS; HEART FAILURE; HUMANS; HYDRALAZINE; ISOSORBIDE DINITRATE; PRACTICE GUIDELINES AS TOPIC;

EID: 84902141731     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2014.04.018     Document Type: Review

References (67)

1. C.W. Yancy, M. Jessup, B. Bozkurt, F.A. Masoudi, J. Butler, P.E. McBride, D.E. Casey Jr., J.J. McMurray, M.H. Drazner, J.E. Mitchell, G.C. Fonarow, P.N. Peterson, S.A. Geraci, T. Horwich, J.L. Januzzi, M.R. Johnson, E.K. Kasper, W.C. Levy, B. Riegel, F. Sam, L.W. Stevenson, W.H. Tang, E.J. Tsai, and B.L. Wilkoff 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 62 2013 e147 e239
2. V.L. Roger, A.S. Go, D.M. Lloyd-Jones, E.J. Benjamin, J.D. Berry, W.B. Borden, D.M. Bravata, S. Dai, E.S. Ford, C.S. Fox, H.J. Fullerton, C. Gillespie, S.M. Hailpern, J.A. Heit, V.J. Howard, B.M. Kissela, S.J. Kittner, D.T. Lackland, J.H. Lichtman, L.D. Lisabeth, D.M. Makuc, G.M. Marcus, A. Marelli, D.B. Matchar, C.S. Moy, D. Mozaffarian, M.E. Mussolino, G. Nichol, N.P. Paynter, E.Z. Soliman, P.D. Sorlie, N. Sotoodehnia, T.N. Turan, S.S. Virani, N.D. Wong, D. Woo, and M.B. Turner Heart disease and stroke statistics - 2012 update: a report from the American Heart Association Circulation 125 2012 e2 e220
3. National Center for Health Statistics Health, United States, 2012: With Special Feature on Emergency Care 2013 Available at: http://www.cdc.gov/nchs/ data/hus/2012/026.pdf
4. K. Sydow, A. Daiber, M. Oelze, Z. Chen, M. August, M. Wendt, V. Ullrich, A. Mulsch, E. Schulz, J.F. Keaney Jr., J.S. Stamler, and T. Munzel Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance J Clin Investig 113 2004 482 489
5. U. Elkayam, A. Roth, A. Mehra, E. Ostrzega, A. Shotan, D. Kulick, M. Jamison, J.V. Johnston, and S.H. Rahimtoola Randomized study to evaluate the relation between oral isosorbide dinitrate dosing interval and the development of early tolerance to its effect on left ventricular filling pressure in patients with chronic heart failure Circulation 84 1991 2040 2048
6. A. Roth, D. Kulick, L. Freidenberger, R. Hong, S.H. Rahimtoola, and U. Elkayam Early tolerance to hemodynamic effects of high dose transdermal nitroglycerin in responders with severe chronic heart failure J Am Coll Cardiol 9 1987 858 864
7. U. Elkayam, D. Kulick, N. McIntosh, A. Roth, W. Hsueh, and S.H. Rahimtoola Incidence of early tolerance to hemodynamic effects of continuous infusion of nitroglycerin in patients with coronary artery disease and heart failure Circulation 76 1987 577 584
8. A. Roth, A. Shotan, and U. Elkayam A randomized comparison between the hemodynamic effects of hydralazine and nitroglycerin alone and in combination at rest and during isometric exercise in patients with chronic mitral regurgitation Am Heart J 125 1993 155 163
9. H. Gogia, A. Mehra, S. Parikh, M. Ramin, J. Ajit-Uppal, J. Johnson, and U. Elkayam Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure J Am Coll Cardiol 26 1995 1575 1580
10. J.A. Bauer, and H.L. Fung Concurrent hydralazine administration prevents nitroglycerin-induced hemodynamic tolerance in experimental heart failure Circulation 84 1991 35 39
11. J.M. Leiro, E. Alvarez, J.A. Arranz, E. Cano, and F. Orallo Antioxidant activity and inhibitory effects of hydralazine on inducible NOS/COX-2 gene and protein expression in rat peritoneal macrophages Int Immunupharmacol 4 2004 163 177
12. T. Munzel, S. Kurz, S. Rajagopalan, M. Thoenes, W.R. Berrington, J.A. Thompson, B.A. Freeman, and D.G. Harrison Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug J Clin Investig 98 1996 1465 1470
13. J. Hare Nitroso-redox balance in the cardiovascular system New Engl J Med 351 2004 2112 2114
14. J. Loscalzo, and G. Welch Nitric oxide and its role in the cardiovascular system Prog Cardiovasc Dis 38 1995 87 104
15. P.B. Massion, O. Feron, C. Dessy, and J.L. Balligand Nitric oxide and cardiac function: ten years after, and continuing Circ Res 93 2003 388 398
16. P. Pacher, J.S. Beckman, and L. Liaudet Nitric oxide and peroxynitrite in health and disease Physiol Rev 87 2007 315 424
17. R.M. Saraiva, and J.M. Hare Nitric oxide signaling in the cardiovascular system: implications for heart failure Curr Opin Cardiol 21 2006 221 228
18. G. Boerrigter, and J.C. Burnett Jr. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease Cardiovasc Drug Rev 25 2007 30 45
19. D. Fraccarollo, J.D. Widder, P. Galuppo, T. Thum, D. Tsikas, M. Hoffmann, H. Ruetten, G. Ertl, and J. Bauersachs Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction Circulation 118 2008 818 827
20. S. Janssens, P. Pokreisz, L. Schoonjans, M. Pellens, P. Vermeersch, M. Tjwa, P. Jans, M. Scherrer-Crosbie, M.H. Picard, Z. Szelid, H. Gillijns, F. Van de Werf, D. Collen, and K.D. Bloch Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction Circ Res 94 2004 1256 1262
21. D.A. Kass, E. Takimoto, T. Nagayama, and H.C. Champion Phosphodiesterase regulation of nitric oxide signaling Cardiovasc Res 75 2007 303 314
22. D. Rohde, J. Ritterhoff, M. Voelkers, H.A. Katus, T.G. Parker, and P. Most S100A1: a multifaceted therapeutic target in cardiovascular disease J Cardiovasc Transl Res 3 2010 525 537
23. M. Scherrer-Crosbie, R. Ullrich, K.D. Bloch, H. Nakajima, B. Nasseri, H.T. Aretz, M.L. Lindsey, A.C. Vancon, P.L. Huang, R.T. Lee, W.M. Zapol, and M.H. Picard Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice Circulation 104 2001 1286 1291
24. A.L. Taylor, S. Ziesche, C. Yancy, P. Carson, R. D'Agostino, K.C. Ferdinand, M. Taylor, K. Adams, M.L. Sabolinski, M. Worcel, and J.N. Cohn Combination of isosorbide dinitrate and hydralazine in blacks with heart failure New Engl J Med 351 2004 2049 2057
25. H. Lapp, V. Mitrovic, N. Franz, H. Heuer, M. Buerke, J. Wolfertz, W. Mueck, S. Unger, G. Wensing, and R. Frey Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure Circulation 119 2009 2781 2788
26. G.D. Lewis, J. Lachmann, J. Camuso, J.J. Lepore, J. Shin, M.E. Martinovic, D.M. Systrom, K.D. Bloch, and M.J. Semigran Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure Circulation 115 2007 59 66
27. J.N. Cohn, D.G. Archibald, S. Ziesche, J.A. Franciosa, W.E. Harston, F.E. Tristani, W.B. Dunkman, W. Jacobs, G.S. Francis, K.H. Flohr, S. Goldman, F.R. Cobb, P.M. Shah, R. Saunders, R.D. Fletcher, H.S. Loeb, V.C. Hughes, and B. Baker Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study N Engl J Med 314 1986 1547 1552
28. J.N. Cohn, G. Johnson, S. Ziesche, F. Cobb, G. Francis, F. Tristani, R. Smith, W.B. Dunkman, H. Loeb, M. Wong, G. Bhat, S. Goldman, R.D. Fletcher, J. Doherty, C.V. Hughes, P. Carson, G. Cintron, R. Shabetai, and C. Haakenson A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure New Engl J Med 325 1991 303 310
29. P. Carson, S. Ziesche, G. Johnson, and J.N. Cohn Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group J Card Fail 5 1999 178 187
30. A.L. Taylor The African-American Heart Failure Trial (A-HeFT): rationale and methodology J Card Fail 9 2003 S216 S219
31. D.C. Angus, W.T. Linde-Zwirble, S.W. Tam, J.K. Ghali, M.L. Sabolinski, V.G. Villagra, W.C. Winkelmayer, and M. Worcel Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure Circulation 112 2005 3745 3753
32. J.N. Cohn, S.W. Tam, I.S. Anand, A.L. Taylor, M.L. Sabolinski, and M. Worcel Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT J Card Fail 13 2007 331 339
33. P. Carson, S.W. Tam, J.K. Ghali, W.T. Archambault, A. Taylor, J.N. Cohn, V.M. Braman, M. Worcel, and I.S. Anand Relationship of quality of life scores with baseline characteristics and outcomes in the African-American Heart Failure Trial J Card Fail 15 2009 835 842
34. A.L. Taylor, S. Ziesche, C.W. Yancy, P. Carson, K. Ferdinand, M. Taylor, K. Adams, A.Y. Olukotun, E. Ofili, S.W. Tam, M.L. Sabolinski, M. Worcel, and J.N. Cohn Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial Circulation 115 2007 1747 1753
35. Arbor Pharmaceuticals, LLC. BiDil prescribing information. Available at: http://bidil.com/PI.pdf. 2013. Accessed on May 6, 2014.
36. S.W. Tam, M.L. Sabolinski, M. Worcel, M. Packer, and J.N. Cohn Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox Clin Pharmacokinet 46 2007 885 895
37. J.A. Franciosa, K.C. Ferdinand, and C.W. Yancy Treatment of heart failure in African Americans: a consensus statement Congest Heart Fail 16 2010 27 38
38. C. Yancy Heart failure in African Americans: unique etiology and pharmacologic treatment responses J Natl Med Assoc 95 2003 1 12
39. K.C. Ferdinand African American Heart Failure Trial: role of endothelial dysfunction and heart failure in African Americans Am J Cardiol 99 2007 3D 6D
40. A. Damasceno, B.M. Mayosi, M. Sani, O.S. Ogah, C. Mondo, D. Ojji, A. Dzudie, C.K. Kouam, A. Suliman, N. Schrueder, G. Yonga, S.A. Ba, F. Maru, B. Alemayehu, C. Edwards, B.A. Davison, G. Cotter, and K. Sliwa The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries: results of the Sub-Saharan Africa Survey of Heart Failure Arch Intern Med 2012 1 9
41. L. Kalinowski, I.T. Dobrucki, and T. Malinski Race-specific differences in endothelial function: predisposition of African Americans to vascular diseases Circulation 109 2004 2511 2517
42. S. Nesbitt, and R.G. Victor Pathogenesis of hypertension in African Americans Congest Heart Fail 10 2004 24 29
43. A.D. Richardson, and R.W. Piepho Effect of race on hypertension and antihypertensive therapy Int J Clin Pharmacol Ther 38 2000 75 79
44. K. Bibbins-Domingo, M. Pletcher, F. Lin, E. Vittinghoff, J. Gardin, A. Arynchyn, C. Lewis, D. Williams, and S. Hulley Racial differences in incident heart failure among young adults New Engl J Med 360 2009 1179 1190
45. W.B. Kannel, A.L. Dannenberg, and D. Levy Population implications of electrocardiographic left ventricular hypertrophy Am J Cardiol 60 1987 85I 93I
46. R. Lapu-Bula, and E. Ofili From hypertension to heart failure: role of nitric oxide-mediated endothelial dysfunction and emerging insights from myocardial contrast echocardiography Am J Cardiol 99 2007 7D 14D
47. C.W. Yancy, W.T. Abraham, N.M. Albert, R. Clare, W.G. Stough, M. Gheorghiade, B.H. Greenberg, C.M. O'Connor, L. She, J.L. Sun, J.B. Young, and G.C. Fonarow Quality of care of and outcomes for African Americans hospitalized with heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure) registry J Am Coll Cardiol 51 2008 1675 1684
48. K.L. Thomas, A.F. Hernandez, D. Dai, P. Heidenreich, G.C. Fonarow, E.D. Peterson, and C.W. Yancy Association of race/ethnicity with clinical risk factors, quality of care, and acute outcomes in patients hospitalized with heart failure Am Heart J 161 2011 746 754
49. C.W. Yancy, G.C. Fonarow, N.M. Albert, A.B. Curtis, W.G. Stough, M. Gheorghiade, J.T. Heywood, M.L. McBride, M.R. Mehra, C.M. O'Connor, D. Reynolds, and M.N. Walsh Adherence to guideline-recommended adjunctive heart failure therapies among outpatient cardiology practices (findings from IMPROVE HF) Am J Cardiol 105 2010 255 260
50. G.C. Fonarow, C.W. Yancy, A.F. Hernandez, E.D. Peterson, J.A. Spertus, and P.A. Heidenreich Potential impact of optimal implementation of evidence-based heart failure therapies on mortality Am Heart J 161 2011 1024 1030.e3
51. R.O. Bonow, T.G. Ganiats, C.T. Beam, K. Blake, D.E. Casey Jr., S.J. Goodlin, K.L. Grady, R.F. Hundley, M. Jessup, T.E. Lynn, F.A. Masoudi, D. Nilasena, I.L. Pina, P.D. Rockswold, L.B. Sadwin, J.D. Sikkema, C.A. Sincak, J. Spertus, P.J. Torcson, E. Torres, M.V. Williams, and J.B. Wong ACCF/AHA/AMA-PCPI 2011 performance measures for adults with heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures and the American Medical Association-Physician Consortium for Performance Improvement Circulation 125 2012 2382 2401
52. D.M. McNamara, S.W. Tam, M.L. Sabolinski, P. Tobelmann, K. Janosko, A.L. Taylor, J.N. Cohn, A.M. Feldman, and M. Worcel Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: results from the A-HeFT Trial J Am Coll Cardiol 48 2006 1277 1282
53. D.M. McNamara, R. Holubkov, L. Postava, K. Janosko, G.A. MacGowan, M. Mathier, S. Murali, A.M. Feldman, and B. London Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure J Am Coll Cardiol 44 2004 2019 2026
54. E. Brand, N. Chatelain, P. Mulatero, I. Fery, K. Curnow, X. Jeunemaitre, P. Corvol, L. Pascoe, and F. Soubrier Structural analysis and evaluation of the aldosterone synthase gene in hypertension Hypertension 32 1998 198 204
55. J.M. Connell, R. Fraser, S.M. MacKenzie, E.C. Friel, M.C. Ingram, C.D. Holloway, and E. Davies The impact of polymorphisms in the gene encoding aldosterone synthase (CYP11B2) on steroid synthesis and blood pressure regulation Moll Cell Endocrinol 217 2004 243 247
56. N.N. Kumar, A.V. Benjafield, R.C. Lin, W.Y. Wang, M. Stowasser, and B.J. Morris Haplotype analysis of aldosterone synthase gene (CYP11B2) polymorphisms shows association with essential hypertension J Hypertens 21 2003 1331 1337
57. P.O. Lim, T.M. Macdonald, C. Holloway, E. Friel, N.H. Anderson, E. Dow, R.T. Jung, E. Davies, R. Fraser, and J.M. Connell Variation at the aldosterone synthase (CYP11B2) locus contributes to hypertension in subjects with a raised aldosterone-to-renin ratio J Clin Endocrinol Metab 87 2002 4398 4402
58. K. Tsukada, T. Ishimitsu, M. Teranishi, M. Saitoh, M. Yoshii, H. Inada, S. Ohta, M. Akashi, J. Minami, H. Ono, M. Ohrui, and H. Matsuoka Positive association of CYP11B2 gene polymorphism with genetic predisposition to essential hypertension J Hum Hypertens 16 2002 789 793
59. P.C. White, and W.E. Rainey Editorial: polymorphisms in CYP11B genes and 11-hydroxylase activity J Clin Endocrinol Metab 90 2005 1252 1255
60. R. Li, D. Lyn, R. Lapu-Bula, A. Oduwole, P. Igho-Pemu, B. Lankford, J. Morgan, S. Nkemdechi, G. Liu, C. Pack, N. Silvestrov, D.A. von Deutsch, Q. Song, I.K. Abukhalaf, and E. Ofili Relation of endothelial nitric oxide synthase gene to plasma nitric oxide level, endothelial function, and blood pressure in African Americans Am J Hypertens 17 2004 560 567
61. R. Lapu-Bula, A. Quarshie, D. Lyn, A. Oduwole, C. Pack, J. Morgan, S. Nkemdiche, P. Igho-Pemu, A. Onwuanyi, R. Li, and E. Ofili The 894T allele of endothelial nitric oxide synthase gene is related to left ventricular mass in African Americans with high-normal blood pressure J Natl Med Assoc 97 2005 197 205
62. D.M. McNamara, S.W. Tam, M.L. Sabolinski, P. Tobelmann, K. Janosko, L. Venkitachalam, E. Ofili, C. Yancy, A.M. Feldman, J.K. Ghali, A.L. Taylor, J.N. Cohn, and M. Worcel Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A-HeFT trial J Card Fail 15 2009 191 198
63. J.E. Tanus-Santos, M. Desai, and D.A. Flockhart Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants Pharmacogenetics 11 2001 719 725
64. J. Fang, G.A. Mensah, J.B. Croft, and N.L. Keenan Heart failure-related hospitalization in the U.S., 1979 to 2004 J Amer Coll Cardiol 52 2008 428 434
65. K.D. Kochanek, J. Xu, S.L. Murphy, A.M. Minino, and H. Kung Deaths: final data for 2009 Natl Vital Stat Rep 2011 60
66. A.L. Taylor, J. Lindenfeld, S. Ziesche, M.N. Walsh, J.E. Mitchell, K. Adams, S.W. Tam, E. Ofili, M.L. Sabolinski, M. Worcel, and J.N. Cohn Outcomes by gender in the African-American Heart Failure Trial J Amer Coll Cardiol 48 2006 2263 2267
67. M. Marmot Social determinants of health inequalities Lancet 365 2005 1099 1104